Zura Bio is a clinical-stage biotechnology company developing novel medicines for autoimmune and inflammatory diseases by targeting immune-mediated pathways supported by translational evidence, biomarker data, and genetic associations. The company's pipeline includes three in-licensed product candidates: a bispecific antibody targeting IL-17A and BAFF, a monoclonal antibody targeting IL-7 receptor alpha, and a monoclonal antibody targeting IL-33, all in various stages of clinical development or strategic evaluation. The company focuses on patient populations with significant unmet medical needs where current therapies fail to achieve durable disease control, and it outsources manufacturing to contract manufacturers rather than operating its own facilities.